Nanovibronix (NASDAQ:FEED) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Nanovibronix (NASDAQ:FEED) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings assumed coverage on Nanovibronix in a report on Tuesday, January 27th. They issued a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Nanovibronix Price Performance

Shares of FEED opened at $2.01 on Friday. Nanovibronix has a one year low of $0.99 and a one year high of $162.50. The company has a market cap of $2.19 million, a P/E ratio of -0.05 and a beta of 2.26.

Insider Buying and Selling

In other Nanovibronix news, major shareholder Christian Michael Glibert bought 240,000 shares of the firm’s stock in a transaction on Wednesday, January 14th. The shares were acquired at an average cost of $2.67 per share, with a total value of $640,800.00. Following the purchase, the insider directly owned 240,000 shares of the company’s stock, valued at $640,800. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.40% of the company’s stock.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.